iTeos Therapeutics, Inc. (ITOS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about iTeos Therapeutics, Inc. (ITOS)
Company Performance

Current Price

as of Oct 16, 2024

$9.55

P/E Ratio

N/A

Market Cap

$348.78M

Description

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Metrics

Overview

  • HQWatertown, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerITOS
  • Price$9.55+1.38%

Trading Information

  • Market Cap$348.78M
  • Float76.89%
  • Average Daily Volume (1m)603,265
  • Average Daily Volume (3m)551,864
  • EPS-$3.00

Company

  • Revenue$35.00M
  • Rev Growth (1yr)N/A
  • Net Income-$7.13M
  • Gross Margin99.12%
  • EBITDA Margin-39.59%
  • EBITDA-$13.86M
  • EV$23.39M
  • EV/Revenue0.67
  • P/EN/A
  • P/S10.83
  • P/B0.53
Documents